Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2022

Open Access 01-12-2022 | Review

Posttranslational control of lipogenesis in the tumor microenvironment

Authors: Yahui Zhu, Xingrong Lin, Xiaojun Zhou, Edward V. Prochownik, Fubing Wang, Youjun Li

Published in: Journal of Hematology & Oncology | Issue 1/2022

Login to get access

Abstract

Metabolic reprogramming of cancer cells within the tumor microenvironment typically occurs in response to increased nutritional, translation and proliferative demands. Altered lipid metabolism is a marker of tumor progression that is frequently observed in aggressive tumors with poor prognosis. Underlying these abnormal metabolic behaviors are posttranslational modifications (PTMs) of lipid metabolism-related enzymes and other factors that can impact their activity and/or subcellular localization. This review focuses on the roles of these PTMs and specifically on how they permit the re-wiring of cancer lipid metabolism, particularly within the context of the tumor microenvironment.
Literature
1.
2.
3.
Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018;38:27.CrossRef
4.
Xiao X, Tang JJ, Peng C, et al. Cholesterol modification of smoothened is required for hedgehog signaling. Mol Cell. 2017;66:154–62.PubMedCrossRef
5.
Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21:225–45.PubMedCrossRef
6.
Gong J, Lin Y, Zhang H, et al. Reprogramming of lipid metabolism in cancer-associated fibroblasts potentiates migration of colorectal cancer cells. Cell Death Dis. 2020;11:267.PubMedPubMedCentralCrossRef
7.
Kim D, Wu Y, Li Q, Oh YK. Nanoparticle-mediated lipid metabolic reprogramming of T cells in tumor microenvironments for immunometabolic therapy. Nanomicro Lett. 2021;13:31.PubMedPubMedCentral
8.
9.
Alannan M, Fayyad-Kazan H, Trezeguet V, Merched A. Targeting lipid metabolism in liver cancer. Biochemistry. 2020;59:3951–64.PubMedCrossRef
10.
Bort A, Sanchez BG, de Miguel I, Mateos-Gomez PA, Diaz-Laviada I. Dysregulated lipid metabolism in hepatocellular carcinoma cancer stem cells. Mol Biol Rep. 2020;47:2635–47.PubMedCrossRef
11.
Rohrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16:732–49.PubMedCrossRef
12.
Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4–22.PubMedCrossRef
13.
Ping Q, Yan R, Cheng X, et al. Cancer-associated fibroblasts: overview, progress, challenges, and directions. Cancer Gene Ther. 2021;28:984–99.PubMedCrossRef
14.
Yu W, Lei Q, Yang L, et al. Contradictory roles of lipid metabolism in immune response within the tumor microenvironment. J Hematol Oncol. 2021;14:187.PubMedPubMedCentralCrossRef
15.
Hu A, Zhao XT, Tu H, et al. PIP4K2A regulates intracellular cholesterol transport through modulating PI(4,5)P2 homeostasis. J Lipid Res. 2018;59:507–14.PubMedPubMedCentralCrossRef
16.
Xiao J, Luo J, Hu A, et al. Cholesterol transport through the peroxisome-ER membrane contacts tethered by PI(4,5)P2 and extended synaptotagmins. Sci China Life Sci. 2019;62:1117–35.PubMedCrossRef
17.
18.
19.
Calhoun S, Duan L, Maki CG. Acetyl-CoA synthetases ACSS1 and ACSS2 are 4-hydroxytamoxifen responsive factors that promote survival in tamoxifen treated and estrogen deprived cells. Transl Oncol. 2022;19:101386.PubMedPubMedCentralCrossRef
20.
Cheng C, Geng F, Li Z, et al. Ammonia stimulates SCAP/Insig dissociation and SREBP-1 activation to promote lipogenesis and tumour growth. Nat Metab. 2022;4:575–88.PubMedCrossRef
21.
22.
Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology—divergent pathophysiology. Nat Rev Endocrinol. 2017;13:710–30.PubMedCrossRef
23.
Cheng C, Ru P, Geng F, et al. Glucose-mediated N-glycosylation of SCAP is essential for SREBP-1 activation and tumor growth. Cancer Cell. 2015;28:569–81.PubMedPubMedCentralCrossRef
24.
Granchi C. ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism. Eur J Med Chem. 2018;157:1276–91.PubMedCrossRef
25.
Menendez JA, Lupu R. Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opin Ther Targets. 2017;21:1001–16.PubMedCrossRef
26.
Enciu AM, Radu E, Popescu ID, Hinescu ME, Ceafalan LC. Targeting CD36 as biomarker for metastasis prognostic: how far from translation into clinical practice? Biomed Res Int. 2018;2018:7801202.PubMedPubMedCentralCrossRef
27.
Go GW, Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J Biol Med. 2012;85:19–28.PubMedPubMedCentral
28.
Rogers MA, Liu J, Song BL, et al. Acyl-CoA:cholesterol acyltransferases (ACATs/SOATs): enzymes with multiple sterols as substrates and as activators. J Steroid Biochem. 2015;151:102–7.CrossRef
29.
Bovenga F, Sabba C, Moschetta A. Uncoupling nuclear receptor LXR and cholesterol metabolism in cancer. Cell Metab. 2015;21:517–26.PubMedCrossRef
30.
31.
Chistiakov DA, Bobryshev YV, Orekhov AN. Macrophage-mediated cholesterol handling in atherosclerosis. J Cell Mol Med. 2016;20:17–28.PubMedCrossRef
32.
Kemmerer M, Wittig I, Richter F, Brune B, Namgaladze D. AMPK activates LXRalpha and ABCA1 expression in human macrophages. Int J Biochem Cell Biol. 2016;78:1–9.PubMedCrossRef
33.
Bougarne N, Weyers B, Desmet SJ, et al. Molecular actions of PPARalpha in lipid metabolism and inflammation. Endocr Rev. 2018;39:760–802.PubMedCrossRef
34.
Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62:720–33.PubMedCrossRef
35.
36.
37.
Yi M, Li J, Chen S, et al. Emerging role of lipid metabolism alterations in Cancer stem cells. J Exp Clin Cancer Res. 2018;37(1):1–18.
38.
Fernandez LP, de Gomez CM, de Ramirez MA. Alterations of lipid metabolism in cancer: implications in prognosis and treatment. Front Oncol. 2020;10:577420.PubMedPubMedCentralCrossRef
39.
40.
Vriens K, Christen S, Parik S, et al. Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature. 2019;566:403–6.PubMedPubMedCentralCrossRef
41.
Chen L, Chen XW, Huang X, et al. Regulation of glucose and lipid metabolism in health and disease. Sci China Life Sci. 2019;62:1420–58.PubMedCrossRef
42.
Pyne NJ, El Buri A, Adams DR, Pyne S. Sphingosine 1-phosphate and cancer. Adv Biol Regul. 2018;68:97–106.PubMedCrossRef
43.
44.
Sukocheva OA, Furuya H, Ng ML, et al. Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: a novel therapeutic target. Pharmacol Ther. 2020;207:107464.PubMedCrossRef
45.
Nganga R, Oleinik N, Ogretmen B. Mechanisms of ceramide-dependent cancer cell death. Adv Cancer Res. 2018;140:1–25.PubMedCrossRef
46.
Gomez-Larrauri A, Presa N, Dominguez-Herrera A, et al. Role of bioactive sphingolipids in physiology and pathology. Essays Biochem. 2020;64:579–89.PubMedCrossRef
47.
48.
Weatherill AR, Lee JY, Zhao L, et al. Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. J Immunol. 2005;174:5390–7.PubMedCrossRef
49.
50.
Ma XZ, Xiao LL, Liu LT, et al. CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability. Cell Metab. 2021;33:1001–12.PubMedPubMedCentralCrossRef
51.
52.
Kishton RJ, Barnes CE, Nichols AG, et al. AMPK Is Essential to balance glycolysis and mitochondrial metabolism to control T-all cell stress and survival. Cell Metab. 2016;23:649–62.PubMedPubMedCentralCrossRef
53.
Zhang Q, Wang H, Mao C, et al. Fatty acid oxidation contributes to IL-1beta secretion in M2 macrophages and promotes macrophage-mediated tumor cell migration. Mol Immunol. 2018;94:27–35.PubMedCrossRef
54.
Zhao F, Xiao C, Evans KS, et al. Paracrine Wnt5a-beta-catenin signaling triggers a metabolic program that drives dendritic cell tolerization. Immunity. 2018;48:147–60.PubMedPubMedCentralCrossRef
55.
56.
57.
58.
Trempolec N, Degavre C, Doix B, et al. Acidosis-induced TGF-beta2 production promotes lipid droplet formation in dendritic cells and alters their Potential to support anti-mesothelioma T cell response. Cancers. 2020;12(5):1284 (Basel).PubMedCentralCrossRef
59.
Otto AM. Metabolic constants and plasticity of cancer cells in a limiting glucose and glutamine microenvironment-a pyruvate perspective. Front Oncol. 2020;10:596197.PubMedPubMedCentralCrossRef
60.
Corbet C, Bastien E, de Santiago Jesus JP, et al. TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 2020;11:454.PubMedPubMedCentralCrossRef
61.
Hao Y, Li D, Xu Y, et al. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data. BMC Bioinform. 2019;20:195.CrossRef
62.
Li X, Wenes M, Romero P, et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019;16:425–41.PubMedCrossRef
63.
64.
65.
Su P, Wang Q, Bi E, et al. Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages. Cancer Res. 2020;80:1438–50.PubMedPubMedCentralCrossRef
66.
67.
Zhang H, Deng T, Liu R, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;19:43.PubMedPubMedCentralCrossRef
68.
Wu H, Liu B, Chen Z, Li G, Zhang Z. MSC-induced lncRNA HCP5 drove fatty acid oxidation through miR-3619-5p/AMPK/PGC1alpha/CEBPB axis to promote stemness and chemo-resistance of gastric cancer. Cell Death Dis. 2020;11:233.PubMedPubMedCentralCrossRef
69.
70.
71.
72.
73.
74.
Ecker C, Guo L, Voicu S, et al. Differential reliance on lipid metabolism as a salvage pathway underlies functional differences of T cell subsets in poor nutrient environments. Cell Rep. 2018;23:741–55.PubMedPubMedCentralCrossRef
75.
Datta M, Coussens LM, Nishikawa H, Hodi FS, Jain RK. Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am Soc Clin Oncol Educ Book. 2019;39:165–74.PubMedPubMedCentralCrossRef
76.
Cluxton D, Petrasca A, Moran B, Fletcher JM. Differential regulation of human Treg and Th17 cells by fatty acid synthesis and glycolysis. Front Immunol. 2019;10:115.PubMedPubMedCentralCrossRef
77.
78.
Kidani Y, Elsaesser H, Hock MB, et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat Immunol. 2013;14:489–99.PubMedPubMedCentralCrossRef
79.
Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. 2018;96:21–33.PubMedCrossRef
80.
Lee JG, Jaeger KE, Seki Y, et al. Human CD36(hi) monocytes induce Foxp3(+) CD25(+) T cells with regulatory functions from CD4 and CD8 subsets. Immunology. 2021;163:293–309.PubMedPubMedCentralCrossRef
81.
Funaoka H, Kanda T, Fujii H. Intestinal fatty acid-binding protein (I-FABP) as a new biomarker for intestinal diseases. Rinsho Byori Jpn J Clin Pathol. 2010;58:162–8.
82.
Field CS, Baixauli F, Kyle RL, et al. Mitochondrial integrity regulated by lipid metabolism is a cell-intrinsic checkpoint for Treg suppressive function. Cell Metab. 2020;31:422–37.PubMedPubMedCentralCrossRef
83.
84.
Imbert C, Montfort A, Fraisse M, et al. Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1. Nat Commun. 2020;11:437.PubMedPubMedCentralCrossRef
85.
86.
Liu C, Chikina M, Deshpande R, et al. Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8(+) T cell-derived interferon-gamma. Immunity. 2019;51:381–97.PubMedPubMedCentralCrossRef
87.
Pineiro Fernandez J, Luddy KA, Harmon C, O’Farrelly C. Hepatic tumor microenvironments and effects on NK cell phenotype and function. Int J Mol Sci. 2019;20(17):4143.CrossRef
88.
Fu S, He K, Tian C, et al. Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells. Nat Commun. 2020;11(1):1–15.CrossRef
89.
Goossens P, Rodriguez-Vita J, Etzerodt A, et al. Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab. 2019;29:1376–89.PubMedCrossRef
90.
Chen HM, van der Touw W, Wang YS, et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest. 2018;128:5647–62.PubMedPubMedCentralCrossRef
91.
Singh L, Muise ES, Bhattacharya A, et al. ILT3 (LILRB4) promotes the immunosuppressive function of tumor-educated human monocytic myeloid-derived suppressor cells. Mol Cancer Res. 2021;19:702–16.PubMedCrossRef
92.
93.
94.
95.
Tao L, Zhu F, Xu F, et al. Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. Pharmacol Res. 2015;102:123–31.PubMedCrossRef
96.
Liu X, Liu R, Bai Y, et al. Post-translational modifications of protein in response to ionizing radiation. Cell Biochem Funct. 2020;38:283–9.PubMedCrossRef
97.
Tolsma TO, Hansen JC. Post-translational modifications and chromatin dynamics. Essays Biochem. 2019;63:89–96.PubMedCrossRef
98.
99.
Silva AMN, Vitorino R, Domingues MRM, Spickett CM, Domingues P. Post-translational modifications and mass spectrometry detection. Free Radic Biol Med. 2013;65:925–41.PubMedCrossRef
100.
Ke M, Shen H, Wang L, et al. Identification, quantification, and site localization of protein posttranslational modifications via mass spectrometry-based proteomics. Adv Exp Med Biol. 2016;919:345–82.PubMedCrossRef
101.
Elguero B, Gonilski Pacin D, Cárdenas Figueroa C, Fuertes M, Arzt E. Modifications in the cellular proteome and their clinical application. Medicina (B Aires). 2019;79:570–5.
102.
103.
Melo-Braga MN, Ibanez-Vea M, Kulej K, Larsen MR. Comprehensive protocol to simultaneously study protein phosphorylation, acetylation, and N-linked sialylated glycosylation. Methods Mol Biol. 2021;2261:55–72.PubMedCrossRef
104.
105.
Wang Z, Yu T, Huang P. Post-translational modifications of FOXO family proteins (Review). Mol Med Rep. 2016;14:4931–41.PubMedCrossRef
106.
Sikarwar AS, Bhagirath AY, Dakshinamurti S. Effects of post-translational modifications on membrane localization and signaling of prostanoid GPCR-G protein complexes and the role of hypoxia. J Membr Biol. 2019;252:509–26.PubMedCrossRef
107.
Han ZJ, Feng YH, Gu BH, Li YM, Chen H. The post-translational modification, SUMOylation, and cancer (Review). Int J Oncol. 2018;52:1081–94.PubMedPubMedCentral
108.
109.
Wu Z, Huang R, Yuan L. Crosstalk of intracellular post-translational modifications in cancer. Arch Biochem Biophys. 2019;676:108138.PubMedCrossRef
110.
Chang PC, Campbell M, Robertson ES. Human oncogenic herpesvirus and post-translational modifications - phosphorylation and SUMOylation. Front Microbiol. 2016;7:962.PubMedPubMedCentralCrossRef
111.
Ooshima A, Park J, Kim SJ. Phosphorylation status at Smad3 linker region modulates transforming growth factor-beta-induced epithelial-mesenchymal transition and cancer progression. Cancer Sci. 2019;110:481–8.PubMedPubMedCentralCrossRef
112.
Watanabe N, Osada H. Phosphorylation-dependent protein-protein interaction modules as potential molecular targets for cancer therapy. Curr Drug Targets. 2012;13:1654–8.PubMedCrossRef
113.
114.
Humphrey SJ, James DE, Mann M. Protein phosphorylation: a major switch mechanism for metabolic regulation. Trends Endocrinol Metab. 2015;26:676–87.PubMedCrossRef
115.
116.
Anbalagan M, Rowan BG. Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer. Mol Cell Endocrinol. 2015;418(Pt 3):264–72.PubMedCrossRef
117.
Kastrati I, Semina S, Gordon B, Smart E. Insights into how phosphorylation of estrogen receptor at serine 305 modulates tamoxifen activity in breast cancer. Mol Cell Endocrinol. 2019;483:97–101.PubMedPubMedCentralCrossRef
118.
Mevizou R, Sirvent A, Roche S. Control of tyrosine kinase signalling by small adaptors in colorectal cancer. Cancers. 2019;11(5):669 (Basel).PubMedCentralCrossRef
119.
120.
Ubersax JA, Ferrell JE Jr. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol. 2007;8:530–41.PubMedCrossRef
121.
Hanafusa H, Garber EA, Hanafusa T. Transformation by p60src with altered N-terminal sequences. Princess Takamatsu Symp. 1986;17:233–40.PubMed
122.
123.
124.
125.
Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 2011;13:376–88.PubMedPubMedCentralCrossRef
126.
Bakan I, Laplante M. Connecting mTORC1 signaling to SREBP-1 activation. Curr Opin Lipidol. 2012;23:226–34.PubMedCrossRef
127.
Aoki M, Fujishita T. Oncogenic roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol. 2017;407:153–89.PubMed
128.
129.
Lee MS, Kim KJ, Kim D, Lee KE, Hwang JK. meso-Dihydroguaiaretic acid inhibits hepatic lipid accumulation by activating AMP-activated protein kinase in human HepG2 cells. Biol Pharm Bull. 2011;34:1628–30.PubMedCrossRef
130.
O’Neill HM, Lally JS, Galic S, et al. AMPK phosphorylation of ACC2 is required for skeletal muscle fatty acid oxidation and insulin sensitivity in mice. Diabetologia. 2014;57:1693–702.PubMedCrossRef
131.
Rios Garcia M, Steinbauer B, Srivastava K, et al. Acetyl-CoA carboxylase 1-dependent protein acetylation controls breast cancer metastasis and recurrence. Cell Metab. 2017;26:842–55.PubMedCrossRef
132.
Gu L, Zhu Y, Lin X, et al. The IKKbeta-USP30-ACLY axis controls lipogenesis and tumorigenesis. Hepatology. 2021;73:160–74.PubMedCrossRef
133.
Lu XY, Shi XJ, Hu A, et al. Feeding induces cholesterol biosynthesis via the mTORC1-USP20-HMGCR axis. Nature. 2020;588:479–84.PubMedCrossRef
134.
Zhang X, Song Y, Feng M, et al. Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation via AMP-activated protein kinase in the liver. J Lipid Res. 2015;56:963–71.PubMedPubMedCentralCrossRef
135.
Gao T, Li M, Mu G, et al. PKCzeta phosphorylates SIRT6 to mediate fatty acid beta-oxidation in colon cancer cells. Neoplasia. 2019;21:61–73.PubMedCrossRef
136.
Menzies KJ, Zhang H, Katsyuba E, Auwerx J. Protein acetylation in metabolism - metabolites and cofactors. Nat Rev Endocrinol. 2016;12:43–60.PubMedCrossRef
137.
Lin SY, Li TY, Liu Q, et al. GSK3-TIP60-ULK1 signaling pathway links growth factor deprivation to autophagy. Science. 2012;336:477–81.PubMedCrossRef
138.
Li TY, Song L, Sun Y, et al. Tip60-mediated lipin 1 acetylation and ER translocation determine triacylglycerol synthesis rate. Nat Commun. 2018;9:1916.PubMedPubMedCentralCrossRef
139.
Gu L, Zhu Y, Lin X, et al. Stabilization of FASN by ACAT1-mediated GNPAT acetylation promotes lipid metabolism and hepatocarcinogenesis. Oncogene. 2020;39:2437–49.PubMedCrossRef
140.
Song NY, Na HK, Baek JH, Surh YJ. Docosahexaenoic acid inhibits insulin-induced activation of sterol regulatory-element binding protein 1 and cyclooxygenase-2 expression through upregulation of SIRT1 in human colon epithelial cells. Biochem Pharmacol. 2014;92:142–8.PubMedCrossRef
141.
Liu L, Xie B, Fan M, et al. Low-level saturated fatty acid palmitate benefits liver cells by boosting mitochondrial metabolism via CDK1-SIRT3-CPT2 cascade. Dev Cell. 2020;52:196–209.PubMedCrossRef
142.
Li M, Hong W, Hao C, et al. Hepatic stellate cell-specific deletion of SIRT1 exacerbates liver fibrosis in mice. Biochim Biophys Acta Mol Basis Dis. 2017;1863:3202–11.PubMedCrossRef
143.
Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5:11.PubMedPubMedCentralCrossRef
144.
Ducker C, Shaw PE. USP17-mediated de-ubiquitination and cancer: clients cluster around the cell cycle. Int J Biochem Cell Biol. 2021;130:105886.PubMedCrossRef
145.
Ramakrishna S, Suresh B, Baek KH. The role of deubiquitinating enzymes in apoptosis. Cell Mol Life Sci. 2011;68:15–26.PubMedCrossRef
146.
Lim KH, Song MH, Baek KH. Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint. Cell Mol Life Sci. 2016;73:1439–55.PubMedCrossRef
147.
Qi L, Heredia JE, Altarejos JY, et al. TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism. Science. 2006;312:1763–6.PubMedCrossRef
148.
Yu J, Deng R, Zhu HH, et al. Modulation of fatty acid synthase degradation by concerted action of p38 MAP kinase, E3 ligase COP1, and SH2-tyrosine phosphatase Shp2. J Biol Chem. 2013;288:3823–30.PubMedCrossRef
149.
Calvisi DF, Wang C, Ho C, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 2011;140:1071–83.PubMedCrossRef
150.
Menzies SA, Volkmar N, van den Boomen DJ, et al. The sterol-responsive RNF145 E3 ubiquitin ligase mediates the degradation of HMG-CoA reductase together with gp78 and Hrd1. Elife. 2018;7:e40009.PubMedPubMedCentralCrossRef
151.
Jiang LY, Jiang W, Tian N, et al. Ring finger protein 145 (RNF145) is a ubiquitin ligase for sterol-induced degradation of HMG-CoA reductase. J Biol Chem. 2018;293:4047–55.PubMedPubMedCentralCrossRef
152.
Loregger A, Raaben M, Tan J, et al. Haploid mammalian genetic screen identifies UBXD8 as a key determinant of HMGCR degradation and cholesterol biosynthesis. Arterioscler Thromb Vasc Biol. 2017;37:2064–74.PubMedPubMedCentralCrossRef
153.
Hwang S, Nguyen AD, Jo Y, et al. Hypoxia-inducible factor 1alpha activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver. J Biol Chem. 2017;292:9382–93.PubMedPubMedCentralCrossRef
154.
Gelsomino G, Corsetto PA, Campia I, et al. Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. Mol Cancer. 2013;12:137.PubMedPubMedCentralCrossRef
155.
Stevenson J, Luu W, Kristiana I, Brown AJ. Squalene mono-oxygenase, a key enzyme in cholesterol synthesis, is stabilized by unsaturated fatty acids. Biochem J. 2014;461:435–42.PubMedCrossRef
156.
Foresti O, Ruggiano A, Hannibal-Bach HK, Ejsing CS, Carvalho P. Sterol homeostasis requires regulated degradation of squalene monooxygenase by the ubiquitin ligase Doa10/Teb4. Elife. 2013;2:e00953.PubMedPubMedCentralCrossRef
157.
Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science. 2009;325:100–4.PubMedPubMedCentralCrossRef
158.
159.
Huang CJ, Wu D, Khan FA, Huo LJ. DeSUMOylation: an important therapeutic target and protein regulatory event. DNA Cell Biol. 2015;34:652–60.PubMedCrossRef
160.
Yang ST, Yen CJ, Lai CH, et al. SUMOylated CPAP is required for IKK-mediated NF-kappaB activation and enhances HBx-induced NF-kappaB signaling in HCC. J Hepatol. 2013;58:1157–64.PubMedCrossRef
161.
Mei L, Yuan L, Shi W, et al. SUMOylation of large tumor suppressor 1 at Lys751 attenuates its kinase activity and tumor-suppressor functions. Cancer Lett. 2017;386:1–11.PubMedCrossRef
162.
Zubiete-Franco I, Garcia-Rodriguez JL, Lopitz-Otsoa F, et al. SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer. EBioMedicine. 2019;40:406–21.PubMedCrossRef
163.
Li J, Xu Y, Long XD, et al. Cbx4 governs HIF-1alpha to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity. Cancer Cell. 2014;25:118–31.PubMedCrossRef
164.
Cui CP, Wong CC, Kai AK, et al. SENP1 promotes hypoxia-induced cancer stemness by HIF-1alpha deSUMOylation and SENP1/HIF-1alpha positive feedback loop. Gut. 2017;66:2149–59.PubMedCrossRef
165.
Choi HK, Choi KC, Yoo JY, et al. Reversible SUMOylation of TBL1-TBLR1 regulates beta-catenin-mediated Wnt signaling. Mol Cell. 2011;43:203–16.PubMedCrossRef
166.
167.
Peng C, Wong CC. The story of protein arginine methylation: characterization, regulation, and function. Expert Rev Proteomics. 2017;14:157–70.PubMedCrossRef
168.
vanLieshout TL, Ljubicic V. The emergence of protein arginine methyltransferases in skeletal muscle and metabolic disease. Am J Physiol Endocrinol Metab. 2019;317:E1070–80.PubMedCrossRef
169.
170.
Liu L, Zhao X, Zhao L, et al. Arginine methylation of SREBP1a via PRMT5 promotes de novo lipogenesis and tumor growth. Cancer Res. 2016;76:1260–72.PubMedCrossRef
171.
Zhu Y, Gu L, Lin X, et al. Dynamic regulation of ME1 phosphorylation and acetylation affects lipid metabolism and colorectal tumorigenesis. Mol Cell. 2020;77:138–49.PubMedCrossRef
172.
Caron C, Boyault C, Khochbin S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. BioEssays. 2005;27:408–15.PubMedCrossRef
173.
174.
Bengoechea-Alonso MT, Ericsson J. The phosphorylation-dependent regulation of nuclear SREBP1 during mitosis links lipid metabolism and cell growth. Cell Cycle. 2016;15:2753–65.PubMedPubMedCentralCrossRef
175.
Sundqvist A, Bengoechea-Alonso MT, Ye X, et al. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 2005;1:379–91.PubMedCrossRef
176.
Lin HP, Cheng ZL, He RY, et al. Destabilization of fatty acid synthase by acetylation inhibits de novo lipogenesis and tumor cell growth. Cancer Res. 2016;76:6924–36.PubMedPubMedCentralCrossRef
177.
Butler LM, Perone Y, Dehairs J, et al. Lipids and cancer: emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020;159:245–93.PubMedPubMedCentralCrossRef
178.
Pemble CW, Johnson LC, Kridel SJ, Lowther WT. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol. 2007;14:704–9.PubMedCrossRef
179.
Munir R, Lisec J, Swinnen JV, Zaidi N. Too complex to fail? Targeting fatty acid metabolism for cancer therapy. Prog Lipid Res. 2022;85:101143.PubMedCrossRef
180.
181.
Zhu Y, Gu L, Lin X, et al. Ceramide-mediated gut dysbiosis enhances cholesterol esterification and promotes colorectal tumorigenesis in mice. JCI Insight. 2022;7:e150607.PubMedPubMedCentralCrossRef
182.
183.
Liu D, Wong CC, Fu L, et al. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med. 2018;10:eaap9840.PubMedCrossRef
184.
Jump DB, Torres-Gonzalez M, Olson LK. Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation. Biochem Pharmacol. 2011;81:649–60.PubMedCrossRef
185.
Beckers A, Organe S, Timmermans L, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 2007;67:8180–7.PubMedCrossRef
186.
Nath A, Li I, Roberts LR, Chan C. Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Sci Rep. 2015;5:14752.PubMedPubMedCentralCrossRef
187.
188.
Li N, Zhou ZS, Shen Y, et al. Inhibition of the sterol regulatory element-binding protein pathway suppresses hepatocellular carcinoma by repressing inflammation in mice. Hepatology. 2017;65:1936–47.PubMedCrossRef
189.
Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–17.PubMedCrossRef
190.
191.
Bilodeau S, Caron V, Gagnon J, Kuftedjian A, Tremblay A. A CK2-RNF4 interplay coordinates non-canonical SUMOylation and degradation of nuclear receptor FXR. J Mol Cell Biol. 2017;9:195–208.PubMedPubMedCentralCrossRef
192.
Kim DH, Xiao Z, Kwon S, et al. A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. EMBO J. 2015;34:184–99.PubMedCrossRef
193.
Zhu Y, Gu L, Lin X, et al. USP19 exacerbates lipogenesis and colorectal carcinogenesis by stabilizing ME1. Cell Rep. 2021;37:110174.PubMedCrossRef
194.
Zhang Q, He Y, Luo N, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179:829–45.PubMedCrossRef
195.
Nambiar DK, Deep G, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1. Oncotarget. 2014;5:10017–33.PubMedPubMedCentralCrossRef
196.
Zheng M, Mullikin H, Hester A, et al. Development and validation of a novel 11-gene prognostic model for serous ovarian carcinomas based on lipid metabolism expression profile. Int J Mol Sci. 2020;21:9169.PubMedCentralCrossRef
197.
198.
Chen RR, Yung MMH, Xuan Y, et al. Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells. Commun Biol. 2019;2:281.PubMedPubMedCentralCrossRef
199.
Pyragius CE, Fuller M, Ricciardelli C, Oehler MK. Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer. Int J Mol Sci. 2013;14:7742–56.PubMedPubMedCentralCrossRef
Metadata
Title
Posttranslational control of lipogenesis in the tumor microenvironment
Authors
Yahui Zhu
Xingrong Lin
Xiaojun Zhou
Edward V. Prochownik
Fubing Wang
Youjun Li
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-022-01340-1

Other articles of this Issue 1/2022

Journal of Hematology & Oncology 1/2022 Go to the issue

Research

Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses

Review

The dual role of autophagy in acute myeloid leukemia

Research

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

Review

Drugging KRAS: current perspectives and state-of-art review

Research

Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma

Correspondence

Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits